400-8-075
| 规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
|---|---|---|---|---|---|---|---|---|---|
| 00mg | ￥ ȁǫǶĩĠĠ | > 0 | > 0 | -- | -- | -- | ￥ ȁǫǶĩĠĠ | - + | |
| 50mg | ￥ ǶǫȁĩĠĠ | > 0 | > 0 | -- | -- | -- | ￥ ǶǫȁĩĠĠ | - + | |
| g | ￥ ƞǶǃĩĠĠ | 0 | > 0 | -- | -- | -- | ￥ ƞǶǃĩĠĠ | - + | |
| 5g | ￥ ljȁljĴĩĠĠ | 9 | -- | -- | -- | -- | ￥ ljȁljĴĩĠĠ | - + | |
| 0g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
| 5g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
| 00g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
3.34
[]. Alfredo Berruti, et al. Enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 0 Dec 0;367(5):448; author reply 448-9.
[]. David End, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV300. Cancer Res. 03 May ;73(9):96.
[3]. Fernand Labrie, et al. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology. J Steroid Biochem Mol Biol. 05 Jan:45:44-56.
[4]. I Ouzaid, et al. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come]. Prog Urol. 03 Jan;3():-7.
[5]. Julie N Graff, et al. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology. 03 Feb;8():38-3.
H30-H3-H33
P6-P64-P70-P7-P80-P30+P35-P304+P340-P330-P36-P363-P405-P50
6.
8
743 现货
￥ ǃȬƏĩĠĠ -00mg
3034 货期咨询
87397 货期咨询
￥ ǃȬǶĩĠĠ -50mg
4960 货期咨询
95736 货期咨询
30345 货期咨询
￥ ǶljĴǃĩĠĠ -g
88995 货期咨询
￥ ȁǫǃǫĩĠĠ -g
95396 货期咨询
87593 货期咨询
87585 货期咨询
沪ICP备709645号
